Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (Mesalamine) Delayed-Release Tablets For Moderately Active Ulcerative Colitis
Procter & Gamble Pharmaceuticals (P&GP) announced the availability of Asacol HD (mesalamine) delayed-release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammation of the lining of the colon and rectum and is typically characterized by flares followed by periods of remission. Moderately active UC is characterized by tougher symptoms than mildly active UC. Asacol HD is proven to help treat these tougher flares of moderately active UC. Asacol HD was approved by the U.S. Food and Drug Administration (FDA) based on evaluations from the ASCEND studies [Assessing the Safety and Clinical Efficacy of a New Dose of 5-ASA (4.8 g/day 800 mg tablet)].
generic viagra online
A Surprise "Spark" For Pre-Cancerous Colon Polyps
Researchers at the Huntsman Cancer Institute (HCI) at the University of Utah studied the events leading to colon cancer and found that an unexpected protein serves as the "spark" that triggers formation of colon polyps, the precursors to cancerous tumors.
News of the day
$29.4 Million Grant Establishes CTSI At NYU In Partnership With Health And Hospitals Corporation
NYU and NYU School of Medicine received a $29.4 million, five-year Clinical and Translational Science Award from the National Institutes of Health (NIH) to establish a University-wide Clinical & Translational Science Institute (CTSI) in partnership with the New York City Health and Hospitals Corporation (HHC). The funding is designed to train medical researchers, more rapidly advance science from the lab to the patient to the community and to allow researchers to explore mechanisms of health disparities and develop evidence-based approaches targeted at their reduction. With this grant, NYU, the NYU School of Medicine and HHC will become part of a network of 46 existing Clinical and Translational Science centers based at academic medical centers around the country.
Sexual Health

Internal Audit Of A Comprehensive IMRT Program For Prostate Cancer: A Model For Centers In Developing Countries?

UroToday.com - During the last economic boom of 2003-2007, cancer centers in second and third-tier countries across the globe made significant investments in radiotherapy infrastructure, acquiring state-of-the-art technologies such as intensity modulated radiotherapy, image-guided radiotherapy, proton therapy and stereotactic radiotherapy, to mention a few. This rapid expansion was partly brought on by competition in the burgeoning global medical tourism industry, and partly by the availability of easy credit, the hallmark of the last economic expansion and the current calamitous downturn. Competition in medical tourism is particularly acute in Asia, where estimates of revenue are of at least USD$4 billion by 2012 in this region alone. In 2007, Asia represented 12.7% of the global medical tourism market with 2.9 million patients and generated revenues of USD$3.4 billion. Reasons for this growing industry include improvements in medical standards, growing prosperity, comparatively weaker Asian currencies (and hence greater affordability), and convenient international travel. The current major players in Southeast Asia include Thailand, India, Singapore and Malaysia. Yet little has been published about the implementation of adequate quality assurance and safeguards in all aspects of patient management, especially with cutting-edge equipment. Thus, this study was designed to illustrate the quality assurance steps that were taken at the National University Hospital (NUH), a tertiary cancer center in Singapore. Intensity-modulated radiotherapy (IMRT), an advanced form of radiotherapy delivery that achieves highly conformal radiation, is widely practiced in Western countries. At NUH, it was carefully introduced into clinical practice in 2005. A number of quality assurance steps were introduced in their process. This study focused on the dosimetric quality assurance, i.e., did the radiotherapy treatment plans achieve the pre-defined 18 dose objectives for prostate cancer. From 2005 to 2008, 76 patients with prostate cancer received IMRT, representing 1,140 evaluable dosimetric endpoints. Of these 1,140 endpoints, only 3% failed to meet the protocol criteria. At the weekly departmental quality assurance rounds, none of the plans were deemed to have a major protocol violation. Among these 76 patients, there were 2 cases each of acute and late grade 3-4 toxicities. In summary, the proposed comprehensive, practice-adapted quality assurance measures hopefully serve as a model for other cancer centers contemplating the development of an IMRT program. Written by Hans T. Chung, MD, FRCPC*, and Ping Xia, PhD** as part of Beyond the Abstract on UroToday.com * Department of Radiation Oncology, Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. ** Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH. UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009